Oppenheimer analyst Esther Rajavelu lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $68.00 (from $70.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE